Natus Medical Incorporated to Acquire Micromed Holding SAS

Exciting combination of product solutions will create a leading neurodiagnostic and neuromonitoring portfolio supported by an organization of knowledgeable and passionate experts.

MIDDLETON, Wis., Dec. 2, 2022 /PRNewswire/ -- Natus Medical Incorporated (the "Company" or "Natus"), a leading provider of medical device solutions focused on the screening, diagnosis and treatment of central nervous and sensory system disorders, has entered into a definitive agreement to acquire Micromed Holding SAS ("Micromed Group" or "Micromed"), a global provider of neurophysiology solutions. The transaction is expected to close in early 2023, subject to the receipt of regulatory approvals.

The acquisition of Micromed will be the first transaction by Natus since being acquired by the ArchiMed Group ("ARCHIMED") in July of this year. "We are pleased to make this first growth-oriented investment as an ARCHIMED portfolio company," said Thomas J. Sullivan, Natus Chief Executive Officer. "The breadth and depth of clinical expertise in Natus and Micromed will enable us to bring exciting innovation to our neuroscience customers and their patients around the globe,"

Together, Natus and Micromed will provide customers with a best-in-class portfolio of neurodiagnostic and neuromonitoring solutions. A Natus legacy of over 85 years of neurodiagnostic leadership including brands such as NeuroWorks®/SleepWorks™, Natus Quantum®, Grass ®, Nicolet®, Xltek®, Embla®, Dantec™ TECA® and others will combine with the complete line of Micromed solutions including BRAIN QUICK®/MYOQUICK®, NEUROWERK®, SleepRT® and MOBERG. The products will also enable a strong platform for new product development in electroencephalography (EEG), polysomnography (PSG), electromyography (EMG), and intensive care unit (ICU) monitoring through the integration of the best aspects of both product portfolios, including backward compatibility.